GEA confirms €4m containment contract with Bangladeshi generics manufacturer

Published: 30-Jul-2015

Shook hands on the deal at ACHEMA

GEA, a supplier of equipment and technology to a range of process industries, has confirmed a €4m deal with Bangladesh-based Healthcare Pharmaceuticals Limited (HPL), a manufacturer of branded generic products for the Asia, Africa, Europe and CIS markets.

Under the terms of the contract, GEA will deliver a fully contained 'one-stop-shop' solution for potent oral solid dosage form production to HPL.

The deal was signed at June's ACHEMA exhibition in Frankfurt, Germany.

Muhammed Halimuzzaman, Chief Executive of HPL, said: 'By implementing GEA’s proven manufacturing solutions and innovations, we intend to establish ourselves as a global supplier and operate on a worldwide platform. We see GEA as a quality provider of the latest technological advances and by investing in best-in-class equipment, we can maximise our R&D efforts and capitalise on the very worthwhile expenditure by getting first-rate products to market quicker.'

HPL said it also appreciates that GEA has a strong regional presence, thereby ensuring close proximity and support.

GEA will provide a fully integrated and contained (OEB 5) 800 L granulation line for hormone-based products with an STTWA of 1–10µg/m3.

The end-to-end solution provides API dispensing through high containment valves to the contained loading of a GEA tablet press. Both wet granulation and direct compression tablet production can be accommodated.

Navin Lakhanpaul, GEA’s VP Sales & Marketing, Pharma, added: 'I am delighted that HPL is buying from GEA. We are a world-leading supplier of innovative technology driven solutions and this agreement further consolidates our long-term and loyal partnership.'

GEA and HPL first collaborated in 2013 with the delivery of an integrated PharmaConnect system for the research and development of highly potent cytotoxic applications.

You may also like